Jazz Pharmaceuticals plc – Research Coverage Started at JPMorgan Chase & Co. (JAZZ)
Investment analysts at JPMorgan Chase & Co. assumed coverage on shares of Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) in a note issued to investors on Tuesday. The firm set an “overweight” rating and a $190.00 price target on the stock. JPMorgan Chase & Co.’s target price would indicate a potential upside of 24.58% from the stock’s previous close.
In other Jazz Pharmaceuticals plc – news, EVP Suzanne Sawochka Hooper sold 1,185 shares of Jazz Pharmaceuticals plc – stock in a transaction dated Tuesday, August 12th. The stock was sold at an average price of $133.15, for a total transaction of $157,782.75. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.
Several other analysts have also recently commented on the stock. Analysts at Zacks reiterated a “neutral” rating on shares of Jazz Pharmaceuticals plc – in a research note on Thursday, August 7th. They now have a $150.00 price target on the stock. Separately, analysts at Piper Jaffray raised their price target on shares of Jazz Pharmaceuticals plc – from $200.00 to $208.00 in a research note on Wednesday, August 6th. Finally, analysts at FBR Capital Markets cut their price target on shares of Jazz Pharmaceuticals plc – from $214.00 to $213.00 in a research note on Wednesday, August 6th. Six equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $174.85.
Shares of Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) opened at 152.51 on Tuesday. Jazz Pharmaceuticals plc – has a 52 week low of $80.20 and a 52 week high of $176.60. The stock has a 50-day moving average of $145.4 and a 200-day moving average of $144.7. The company has a market cap of $9.184 billion and a P/E ratio of 109.46.
Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) last released its earnings data on Tuesday, August 5th. The company reported $2.05 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.92 by $0.13. The company had revenue of $291.23 million for the quarter, compared to the consensus estimate of $273.39 million. During the same quarter in the previous year, the company posted $1.43 earnings per share. The company’s revenue for the quarter was up 39.8% on a year-over-year basis. On average, analysts predict that Jazz Pharmaceuticals plc – will post $8.18 earnings per share for the current fiscal year.
Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry.